全球第三大仿制药商阿特维斯（Actavis）2月18日表示，计划耗资约250亿美元收购森林实验室（Forest Lab），以扩大品牌药产品组合，并增强在美国的市场。
通过此次收购，Actavis将添加阿尔茨海默氏症药物Namenda及一些新药如抗抑郁药物Viibryd至其产品组合。分析师称，此次收购将赋予Actavis更多的话语权，与医院和其他医疗护理提供商进行谈判。
2012年，华生制药（Watson Pharmacyclics）和阿特维斯集团（Actavis Group）通过一笔56亿美元的结盟，成立了新的阿特维斯（Actavis）公司。而过去的一年中，通过收购活动，包括85亿美元收购爱尔兰制药商华纳奇尔科特（Warner Chilcott），Actavis已迅速成长。
Actavis总部位于都柏林，提供仿制药及像泌尿外科和妇女保健领域的特殊产品。产品组合包括骨质疏松症药物Actonel。Actavis最大的竞争对手为梯瓦制药（Teva Pharmacyclics）和迈兰（Mylan）。
Forest Lab总部位于纽约，其数个重磅药物已被仿制药竞争严重挤压，包括焦虑症及抑郁症药物Lexapro，同时Namenda也将于2015年失去专利保护。该公司已推出了数个新药物，包括Viibryd和肺病药物Daliresp，以帮助弥补这些损失。今年1月，Forest Lab刚耗资29亿美元收购Aptalis制药，后者生产肠胃病及囊性纤维化治疗药物。
英文原文：
Actavis PLC plans to buy Forest Laboratories Inc. in an approximately $25 billion deal that will boost the Irish drugmaker's presence in U.S. primary-care doctor offices and bulk up its portfolio of branded drugs.
Actavis will add the Alzheimer's disease treatment Namenda, and newer drugs like the antidepressant Viibryd to its product portfolio with the latest in a string of multi-billion dollar acquisitions that have swelled the drugmaker's size in recent years.
Analyst say the acquisition also gives Actavis more negotiating muscle with hospitals and other care providers that also have grown bigger in recent years.
Actavis said Tuesday it will pay Forest shareholders $26.04 in cash and a portion of an Actavis share for each Forest share. The total, per-share price of $89.48 represents a premium of about 25 percent over Forest's closing price Friday of $71.39.
Shares of New York-based Forest soared nearly 30 percent to $92.50 in Tuesday morning trading. That's well above the price Actavis offered, a sign that shareholders believe Forest will receive a better offer. U.S.-traded shares of Dublin-based Actavis climbed 7.6 percent, or $14.56, to $206.04.
Actavis was formed in 2012 through a $5.6 billion tie-up between generic drugmaker Watson Pharmaceuticals and Actavis Group. It has grown rapidly through acquisitions, including an $8.5 billion deal it closed last fall to buy another Irish drugmaker, Warner Chilcott.
It offers generic drugs and specialty products in areas like urology and women's health. That portfolio includes the osteoporosis treatment Actonel.
New York-based Forest Labs has been squeezed by generic competition to some of its biggest drugs, including its anxiety and depression drug Lexapro. It also faces the loss of patent protection for Namenda in 2015. The company has launched several new drugs, including Viibryd and the lung disease drug Daliresp, to help make up for those losses.
Forest took an annual loss in fiscal 2012, its first in 15 years, and has faced pressure from billionaire investor Carl Icahn, its second-largest shareholder, according to FactSet.
The company has been working to cut costs under new CEO Brent Saunders, who replaced long-standing leader Howard Solomon last fall. The new leader, backed by Icahn, launched plans to cut about 500 jobs as part of a goal to trim $500 million in costs.
Tuesday's announcement comes a few weeks after Forest completed its own acquisition, a $2.9 billion purchase of Aptalis, a company that makes treatments for gastrointestinal problems and cystic fibrosis.
关键词： 仿制药 阿特维斯 收购 Forest Lab
免责声明：
本文仅供专业人士学术交流探讨，不作为诊疗及用药依据。
如有侵权，请联系我们删除